NCT02997176View on ClinicalTrials.gov

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 12, 2020

Study Completion Date

February 12, 2020

Conditions
Advanced Solid Tumors
Interventions
DRUG

Talazoparib

Daily oral doses of talazoparib 0.5 mg

Trial Locations (11)

32806

Orlando Health, Inc., Orlando

77030

The University of Texas MD Anderson Cancer Center, Houston

90095

UCLA Hematology/Oncology, Los Angeles

90404

UCLA Hematology/Oncology - Santa Monica, Santa Monica

90505

UCLA Torrance Oncology, Torrance

91326

UCLA Hematology/Oncology - Porter Ranch, Porter Ranch

91355

UCLA Hematology/Oncology - Santa Clarita, Valencia

91801

UCLA Hematology/Oncology - Alhambra, Alhambra

92835

St. Joseph Heritage Healthcare, Fullerton

St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton

93309

CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) | Biotech Hunter | Biotech Hunter